China Medical System receives NMPA nod to start clinical trial of oral AMD therapy CMS-D017

SGX Filings

Jul 15

China Medical System Holdings Limited announced that on Jul, 15 2026 China’s National Medical Products Administration granted a Drug Clinical Trial Approval Notice for CMS-D017, the group’s self-developed oral complement factor B inhibitor, allowing the company to initiate clinical trials in patients with age-related macular degeneration (AMD).

CMS-D017 is a selective small-molecule agent that blocks the alternative complement pathway, a mechanism linked to the progression of AMD. The company said pre-clinical studies demonstrated favourable efficacy and safety.

The candidate is also being developed for paroxysmal nocturnal hemoglobinuria, complement-mediated kidney diseases and potentially myasthenia gravis. It previously secured NMPA approvals to begin trials for paroxysmal nocturnal hemoglobinuria on Jan, 30 2026 and for complement-mediated kidney diseases on Feb, 3 2026.

China Medical System added that, if approved, CMS-D017 would broaden the portfolio of its ophthalmology subsidiary, CMS Vision, alongside existing products Beovu, Lucentis and Augentropfen Stulln Mono Eye Drops.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1156868759"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156868759\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156868759?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156868759","market":"sg","top_or_hot":-1,"title":"China Medical System receives NMPA nod to start clinical trial of oral AMD therapy CMS-D017","media":"SGX Filings","content":"<p>China Medical System Holdings Limited announced that on Jul, 15 2026 China’s National Medical Products Administration granted a Drug Clinical Trial Approval Notice for CMS-D017, the group’s self-developed oral complement factor B inhibitor, allowing the company to initiate clinical trials in patients with age-related macular degeneration (AMD).</p>\n<p>CMS-D017 is a selective small-molecule agent that blocks the alternative complement pathway, a mechanism linked to the progression of AMD. The company said pre-clinical studies demonstrated favourable efficacy and safety.</p>\n<p>The candidate is also being developed for paroxysmal nocturnal hemoglobinuria, complement-mediated kidney diseases and potentially myasthenia gravis. It previously secured NMPA approvals to begin trials for paroxysmal nocturnal hemoglobinuria on Jan, 30 2026 and for complement-mediated kidney diseases on Feb, 3 2026.</p>\n<p>China Medical System added that, if approved, CMS-D017 would broaden the portfolio of its ophthalmology subsidiary, CMS Vision, alongside existing products Beovu, Lucentis and Augentropfen Stulln Mono Eye Drops.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Medical System receives NMPA nod to start clinical trial of oral AMD therapy CMS-D017</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Medical System receives NMPA nod to start clinical trial of oral AMD therapy CMS-D017\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083912268\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">SGX Filings </p>\n<p class=\"h-time\">2026-07-15 19:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Medical System Holdings Limited announced that on Jul, 15 2026 China’s National Medical Products Administration granted a Drug Clinical Trial Approval Notice for CMS-D017, the group’s self-developed oral complement factor B inhibitor, allowing the company to initiate clinical trials in patients with age-related macular degeneration (AMD).</p>\n<p>CMS-D017 is a selective small-molecule agent that blocks the alternative complement pathway, a mechanism linked to the progression of AMD. The company said pre-clinical studies demonstrated favourable efficacy and safety.</p>\n<p>The candidate is also being developed for paroxysmal nocturnal hemoglobinuria, complement-mediated kidney diseases and potentially myasthenia gravis. It previously secured NMPA approvals to begin trials for paroxysmal nocturnal hemoglobinuria on Jan, 30 2026 and for complement-mediated kidney diseases on Feb, 3 2026.</p>\n<p>China Medical System added that, if approved, CMS-D017 would broaden the portfolio of its ophthalmology subsidiary, CMS Vision, alongside existing products Beovu, Lucentis and Augentropfen Stulln Mono Eye Drops.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"8A8.SI","symbol_name":"康哲药业控股有限公司","start_time":0,"source_url":"","article_id":"1156868759","we_media_id":"1083912268","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156868759","pubTimestamp":1784113807,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"SGX Filings","introduction":"Fastest News on SGX Filings ","home_visible":1,"id":"1083912268","head_image":"https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39"},"summary":"China Medical System Holdings Limited announced that on Jul, 15 2026 China’s National Medical Products Administration granted a Drug Clinical Trial Approval Notice for CMS-D017, the group’s...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"8A8.SI":"康哲药业控股有限公司"},"translate_title":"中国医药系统获NMPA批准启动口服AMD疗法CMS-D017临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"8A8.SI":1},"content_text":"China Medical System Holdings Limited announced that on Jul, 15 2026 China’s National Medical Products Administration granted a Drug Clinical Trial Approval Notice for CMS-D017, the group’s self-developed oral complement factor B inhibitor, allowing the company to initiate clinical trials in patients with age-related macular degeneration (AMD).\nCMS-D017 is a selective small-molecule agent that blocks the alternative complement pathway, a mechanism linked to the progression of AMD. The company said pre-clinical studies demonstrated favourable efficacy and safety.\nThe candidate is also being developed for paroxysmal nocturnal hemoglobinuria, complement-mediated kidney diseases and potentially myasthenia gravis. It previously secured NMPA approvals to begin trials for paroxysmal nocturnal hemoglobinuria on Jan, 30 2026 and for complement-mediated kidney diseases on Feb, 3 2026.\nChina Medical System added that, if approved, CMS-D017 would broaden the portfolio of its ophthalmology subsidiary, CMS Vision, alongside existing products Beovu, Lucentis and Augentropfen Stulln Mono Eye Drops.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}